<DOC>
	<DOC>NCT02348606</DOC>
	<brief_summary>This trial is a 12 week, randomized, double-blind, placebo controlled, multicenter, 5-arm parallel group study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.</brief_summary>
	<brief_title>"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<criteria>Major 1. Male or female between 18 and 75 years of age, inclusive 2. Diagnosis of OSA according to ICSD3 criteria 3. Body mass index from 18 to &lt;45 kg/m2 4. Consent to use a medically acceptable method of contraception 5. Willing and able to provide written informed consent Major 1. Female subjects who are pregnant, nursing, or lactating 2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness 3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM5 criteria 4. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator. 5. History of bariatric surgery within the past year or a history of any gastric bypass procedure 6. Presence or history of significant cardiovascular disease 7. Use of any overthecounter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness 8. Received an investigational drug in the past 30 days or five halflives 9. Previous exposure to or participation in a clinical trial of JZP110 (ADXN05, R228060, or YKP10A) 10. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalaninederived products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>